3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Lymphoma, Non-Hodgkin
6
Lymphoma, B-Cell
5
Recurrence
4
Burkitt Lymphoma
4
Neoplasm, Residual
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Follicular
3
Lymphoma
3
Leukemia, Myeloid, Acute
3
Leukemia
3
Multiple Myeloma
2
Lymphoma, Mantle-Cell
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Glioma
2
Glioblastoma
2
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Stomach Neoplasms
1
Solid Tumors
1
Simpson-Golabi-Behmel syndrome
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Pleural Effusion, Malignant
1
Platinum-Resistant Ovarian Carcinoma
1
Pancreatic Neoplasms
1
Interventions
Temozolomide
48
Radiotherapy
26
Radiation
13
Chemotherapy, Adjuvant
9
O(6)-benzylguanine
8
Irinotecan
8
Carmustine
8
Surgical Procedures, Operative
7
Magnetic Resonance Spectroscopy
6
Erlotinib Hydrochloride
6
motexafin gadolinium
5
Radiotherapy, Intensity-Modulated
5
Imatinib Mesylate
5
sargramostim
4
Radiotherapy, Conformal
4
Hydroxyurea
4
Gene Expression Profiling
4
lonafarnib
3
Radiosurgery
3
Immunohistochemistry
3
Genetic Therapy
3
Filgrastim
3
Drug Therapy
3
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
3
vandetanib
2
tipifarnib
2
temsirolimus
2
cediranib
2
aldesleukin
2
Vorinostat
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Gliosarcoma
×
Immunotherapy, Adoptive
×
Clear all
NCT02664363
2023-02-17
ExCeL
Duke University
Phase 1
Terminated
3 enrolled
8 charts